Ocean Biomedical’s JV partner Virion presents positive oncology data at SITC 2023
usx:ocea Blog PostOcean Biomedical announces loan commitment of up to $10 million from largest stockholder
usx:ocea Blog PostOcean Biomedical provides update on programs in malaria, fibrosis, and multiple cancers
usx:ocea Blog PostOcean Biomedical’s share price target averages $18.21 amid continued progress in research programs
usx:ocea Blog PostOcean Biomedical shares details of its successful lung cancer program on World Lung Cancer Day
usx:ocea Blog PostOcean Biomedical focuses its malaria program to address chronic malaria crisis in sub-Saharan Africa
usx:ocea Blog PostOcean Biomedical extends patent rights for idiopathic pulmonary fibrosis discovery to Europe
usx:ocea Blog PostFundamental Research Corp. raises Ocean Biomedical’s price target to $17.63 per share
usx:ocea Blog PostOcean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
usx:ocea Blog PostTaglich Brothers initiates coverage of Ocean Biomedical, with price target of $20
usx:ocea Blog PostOcean Biomedical (OCEA) announces patent award for novel cancer immunotherapy treatment
usx:ocea Blog PostOcean Biomedical co-founder Jonathan Kurtis presents detailed data on malaria vaccine at conference
usx:ocea Blog PostOcean Biomedical co-founder Jack Elias to receive US patent for pulmonary fibrosis treatments
usx:ocea Blog Post